Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer.

A. Gillespie,T. Broadhead,S. Chan,J. Owen,A. Farnsworth,M. Sopwith,R. Coleman
DOI: https://doi.org/10.1023/A:1008349300781
IF: 51.769
2000-06-01
Annals of Oncology
Abstract:
What problem does this paper attempt to address?